GlaxoSmithKline and Merck & Co. enter HPV agreement
Merck & Co. Inc and GlaxoSmithKline (GSK) have entered into a cross-license and settlement agreement for certain patent rights related to human papillomavirus (HPV) vaccine.
Merck & Co. Inc and GlaxoSmithKline (GSK) have entered into a cross-license and settlement agreement for certain patent rights related to human papillomavirus (HPV) vaccine.
GSK will receive an upfront payment and royalties from Merck & Co. based on sales of an HPV vaccine when launched. Further financial details and terms were not disclosed.
The agreement resolves competing intellectual property claims related to the Merck & Co. and GSK vaccine candidates, but both will still continue with their own independent r&d and, after appropriate regulatory reviews and approval, commercialisation activities for their respective investigational HPV vac-cine candidates.